



Summary of Studies Supporting USDA Product Licensure

Establishment Name	Intervet Inc.
USDA Vet Biologics Establishment Number	165A
Product Code	1905.23
True Name	Rabies Vaccine, Killed Virus
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	EquiRab - Merck Animal Health Prestige EquiRab - Merck Animal Health
Date of Compilation Summary	April 10, 2018

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy												
Pertaining to	Rabies Virus (RV)												
Study Purpose	To demonstrate efficacy against Rabies virus 14 months after vaccination.												
Product Administration	One dose administered intramuscularly (IM)												
Study Animals	26 vaccinates and 11 controls horses were used at 4 months of age.												
Challenge Description	11 vaccinates and 5 control horse were challenged with Rabies virus 14 months post vaccination.												
Interval observed after challenge	Horses were observed daily for 90 days post-challenge.												
Results	<p>Efficacy was demonstrated according to 9CFR 113.209(b).</p> <table border="1"> <thead> <tr> <th>Group</th> <th>Number of Animals</th> <th>Number Challenged</th> <th>Number of Deaths attributed to RV by DFA</th> </tr> </thead> <tbody> <tr> <td>Vaccinates</td> <td>26</td> <td>11</td> <td>0</td> </tr> <tr> <td>Controls</td> <td>11</td> <td>5</td> <td>4</td> </tr> </tbody> </table> <p>DFA is direct fluorescent antibody titer</p> <p>Raw data shown on attached page.</p>	Group	Number of Animals	Number Challenged	Number of Deaths attributed to RV by DFA	Vaccinates	26	11	0	Controls	11	5	4
Group	Number of Animals	Number Challenged	Number of Deaths attributed to RV by DFA										
Vaccinates	26	11	0										
Controls	11	5	4										
USDA Approval Date	March 1, 2006												

Horse ID #	Treatment Group	Sex	Status	Horse ID #	Treatment Group	Sex	Status
273	Vaccinate	M	Survived	278	Control	F	Survived
285	Vaccinate	F	Survived	309	Control	M	Euthanized**
286	Vaccinate	F	Survived	312	Control	M	Dead
288	Vaccinate	F	Survived	313	Control	F	Dead
289	Vaccinate	F	Dead*	315	Control	M	Euthanized**
290	Vaccinate	M	Survived				
292	Vaccinate	M	Survived				
293	Vaccinate	F	Survived				
295	Vaccinate	M	Survived				
300	Vaccinate	M	Survived				
305	Vaccinate	F	Survived				
Protection 100% (10/10)				Rabies incidence 80% (4/5)			

* The animal died on day 61 post-challenge. Cause of death was determined to be not related to rabies. The absence of rabies virus was confirmed by direct fluorescent antibody titer (DFA) .

** Euthanized following the neurological signs suggestive of rabies.

Study Type	Safety																					
Pertaining to	ALL																					
Study Purpose	To demonstrate safety under field conditions																					
Product Administration	One dose administered intramuscularly																					
Study Animals	992 horses from 3 states. 413 horses were 4 months of age or younger at time of the initial vaccination.																					
Challenge Description	Not applicable																					
Interval observed after challenge	Horses were observed immediately following vaccination and then daily for 3 days post-vaccination																					
Results	<table border="1"> <thead> <tr> <th>Score</th> <th># of Reactions</th> <th>% of Total</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>969</td> <td>97.68</td> </tr> <tr> <td>1</td> <td>15</td> <td>1.51</td> </tr> <tr> <td>2</td> <td>8</td> <td>0.81</td> </tr> <tr> <td>3</td> <td>0</td> <td>0</td> </tr> <tr> <td>4</td> <td>0</td> <td>0</td> </tr> <tr> <td>5</td> <td>0</td> <td>0</td> </tr> </tbody> </table> <p>Score Overview: 0 – No reaction 1 – Localized swelling at or near the injection site, which is not visible; detectable only by palpation. Not clinically significant. 2 – Localized visible swelling at or near the injection site. Not painful. 3 – Localized visible swelling at or near the injection site. Raised, circumscribed and painful. 4 – Visible diffused swelling involving a substantial area around the injection site. Very painful and hot. Horse is stiff and/or reluctant to move. 5 – Generalized or systemic reaction, including anaphylaxis or elevated temperature.</p> <p>All swellings resolved by 4 days post-vaccination.</p>	Score	# of Reactions	% of Total	0	969	97.68	1	15	1.51	2	8	0.81	3	0	0	4	0	0	5	0	0
Score	# of Reactions	% of Total																				
0	969	97.68																				
1	15	1.51																				
2	8	0.81																				
3	0	0																				
4	0	0																				
5	0	0																				
USDA Approval Date	October 23, 2007																					